https://www.thebodypro.com/category/stribild-pro/tag/conference-coverage

The Latest

Fewer Renal or Bone Events With Atripla Than Stribild in Large Database Img

Fewer Renal or Bone Events With Atripla Than Stribild in Large Database

Renal adverse events and fractures proved rare among people taking tenofovir disoproxil fumarate (TDF) as part of a single-tablet regimen in a large U.S. database of insured patients.

Single-Tablet HIV Regimen Containing Tenofovir Alafenamide Improves Bone and Kidney Safety Img

Single-Tablet HIV Regimen Containing Tenofovir Alafenamide Improves Bone and Kidney Safety

A new single-tablet HIV regimen containing tenofovir alafenamide (TAF) offered better bone and kidney safety, according to a study presented at ICAAC/ICC 2015.

HIV Antiretroviral Study Highlights From IAS 2015 Img

HIV Antiretroviral Study Highlights From IAS 2015

We briefly summarize some of the most noteworthy new HIV treatment studies presented at a major research conference that took place this month.

Stribild Safe and Effective in African Americans, 2 Studies Conclude Img

Stribild Safe and Effective in African Americans, 2 Studies Conclude

Stribild, compared to Atripla, was efficacious, durable, well-tolerated and safe in treatment-naive Black adults, and may be a viable switch option for virologically suppressed Black patients looking for regimen modification or simplification.

Promo Image

Switching to Stribild From Non-Nuke or Protease Inhibitor Regimens Works Well

So with all the positive news about integrase inhibitors in initial HIV treatment, is it safe to switch patients from other NNRTI (non-nucleoside reverse transcriptase inhibitor)- or PI (protease inhibitor)-based regimens to integrase inhibitor regim...

Racial Differences Seen in Comparison of Stribild and Atripla as First-Line Therapy Img

Racial Differences Seen in Comparison of Stribild and Atripla as First-Line Therapy

A new study finds that black people are less likely to keep their viral load down on Atripla -- and that more trouble with side effects may be the reason.

Stribild (a.k.a. "Quad") Performs Well for People Over 50, Study Finds Img

Stribild (a.k.a. "Quad") Performs Well for People Over 50, Study Finds

As the HIV community grows older, the HIV research spotlight is shifting with it. A special study of the newly approved four-in-one pill Stribild compared how well the drug works in HIVers over 50 compared to younger people.

Stribild (a.k.a. "Quad") May Slightly Outperform Other Popular First-Line Options, Study Finds Img

Stribild (a.k.a. "Quad") May Slightly Outperform Other Popular First-Line Options, Study Finds

The newly approved four-in-one drug Stribild appears to show somewhat better effectiveness and tolerability than either Atripla or a regimen comprised of Norvir, Reyataz and Truvada, according to combined results from three 48-week studies.

Promo Image

Gilead Quad HIV Drug Causes Fewer Side Effects

Gilead Sciences Inc.'s experimental pill combining four HIV drugs has fewer side effects than the firm's current three-drug Atripla pill, according to data presented Wednesday in Seattle at the 19th Conference on Retroviruses and Opportunistic Infect...

Promo Image

Data Show Gilead's Quad Regimen for HIV Non-Inferior to Protease-Based Regimen at 48 Weeks in Second Pivotal Phase 3 Study

Seattle, Wash. -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced full results from the second pivotal Phase 3 clinical trial (Study 103) of its Quad once-daily single tablet regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disop...